The effect of 5α-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men

…, WJ Bremner, SE Walker, LJ Haberer… - The Journal of …, 2007 - academic.oup.com
Context: Dutasteride and finasteride are 5α-reductase inhibitors (5ARIs) that dramatically
reduce serum levels of dihydrotestosterone (DHT). Objective: Because androgens are …

Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double‐blind, placebo‐, and active‐controlled thorough QT …

P Zuo, LJ Haberer, L Fang, TL Hunt… - The Journal of …, 2014 - Wiley Online Library
Prolongation of the QT interval has been observed with ondansetron and other members of
the 5‐HT 3 antagonist class. This is the first thorough QTc study of ondansetron conducted in …

Distinct pharmacokinetic profile and safety of a fixed‐dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine

LJ Haberer, CM Walls, SE Lener… - … : The Journal of …, 2010 - Wiley Online Library
(Headache 2010;50:357‐373) Objective.— To describe the pharmacokinetic and safety profiles
of sumatriptan 85 mg formulated with RT Technology (RT) and naproxen sodium 500 mg …

Central nervous system uptake kinetics of pentylenetetrazol in the developing rat

LJ Haberer, GM Pollack - Biopharmaceutics & drug disposition, 1991 - Wiley Online Library
The present investigation was undertaken to examine the brain uptake kinetics of the central
nervous system (CNS) stimulant pentylenetetrazol (PTZ) during postnatal development. …

Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1− 48 months

JT Mondick, BM Johnson, LJ Haberer, ME Sale… - European journal of …, 2010 - Springer
Purpose Until recently, ondansetron was approved for the prevention of nausea and
vomiting only in patients older than 2 years. However, as the use of ondansetron in patients …

Chronic stress impairs oxidative metabolism and hepatic excretion of model xenobiotic substrates in the rat.

GM Pollack, JL Browne, J Marton, LJ Haberer - Drug metabolism and …, 1991 - ASPET
Traumatic injury to both hard and soft tissue has been associated with a decrease in the rate
of hepatic drug metabolism. The mechanism(s) underlying this phenomenon have yet to be …

[PDF][PDF] Disposition and protein binding of valproic acid in the developing rat.

LJ Haberer, GM Pollack - Drug metabolism and disposition, 1994 - Citeseer
The dlsposftlon of valprolc acid (VPA) In serum and braIn tissue was #{149} xamlnedIn
developing rats (5, 10, 20, and 60 days postpartum) following both single and multlpi. …

Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine

…, T Abell, R Werkman, LJ Haberer, LJ Hak - Digestive diseases and …, 2000 - Springer
Azathioprine (AZA) is used in the treatment of patients with refractory inflammatory bowel
disease; however, its use is limited because of systemic toxicity associated with long-term use. …

[HTML][HTML] Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates

LJ Haberer, I McSherry, A Cargill… - European journal of clinical …, 2014 - Springer
Purpose Vercirnon is a CCR9 chemokine receptor antagonist being developed for the
treatment of Crohn’s disease. As a variety of concomitant medications are often required for the …

Single‐Dose Pharmacokinetics of the CCR9 Receptor Antagonist Vercirnon in Healthy US and Japanese Subjects

LJ Haberer, K Hacquoil, H Ino… - Clinical …, 2013 - Wiley Online Library
Two randomized, single‐dose, crossover studies were carried out to assess different formulations
and doses of the CCR9 receptor antagonist vercirnon in healthy subjects. US study (n …